Liu Ting, Chen Lilan, Sun Xiangjun, Wang You, Li Shu, Yin Xia, Wang Xinran, Ding Chenhuan, Li He, Di Wen
Department of Gynecology and Obstetrics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Dongfang Road No. 1630, Shanghai, 200127, People's Republic of China.
Tumour Biol. 2014 Mar;35(3):2427-36. doi: 10.1007/s13277-013-1322-x. Epub 2013 Nov 7.
Progesterone and its receptor, progesterone receptor (PGR), have been widely studied for their roles in the onset and development of ovarian cancer. Although numerous epidemiological studies have focused on the association of PGR PROGINS and +331G/A polymorphisms with ovarian cancer susceptibility, presently, available results remain controversial, in part due to low sample sizes. Thus, a meta-analysis is required to evaluate this association. A literature search of PubMed, Embase, Web of Science, CNKI, and CBM databases was performed to retrieve eligible studies published before August 15, 2013. Summary odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of this association. All analyses were done using STATA 12.0 software (Stata Corp., College Station, TX, USA). Seventeen case-control studies with a total of 6,365 cases and 9,998 controls were identified. While no statistically significant association between the PROGINS allele and ovarian cancer risk was found in an overall analysis, a stratified analysis revealed that for Caucasians, never-oral contraceptive (OC) users, and serous tumor patients, there were statistically significant ORs for ovarian cancer risk associated with the mutated PROGINS allele. No significant association, however, between the +331G/A polymorphism and ovarian cancer susceptibility was observed in the overall analyses and subgroup analyses based on ethnicity and histological type. This meta-analysis provides evidence that the PROGINS allele occurs more frequently in ovarian cancer patients and especially in non-OC users and serous cancer patients, indicating that PROGINS may be a risk modifier. No significant association between the +331G/A polymorphism and ovarian cancer was found, even in stratified analyses by ethnicity and histological type. More detailed and well-designed studies are still needed to confirm the role of the PROGINS allele in ovarian cancer development.
孕酮及其受体——孕酮受体（PGR），因其在卵巢癌发生和发展中的作用而受到广泛研究。尽管众多流行病学研究聚焦于PGR PROGINS和+331G/A多态性与卵巢癌易感性的关联，但目前可得的结果仍存在争议，部分原因是样本量较小。因此，需要进行一项荟萃分析来评估这种关联。我们检索了PubMed、Embase、Web of Science、中国知网和中国生物医学文献数据库，以获取2013年8月15日前发表的符合条件的研究。采用汇总比值比（OR）及95%置信区间（CI）来评估这种关联的强度。所有分析均使用STATA 12.0软件（美国德克萨斯州大学站市Stata公司）完成。共纳入17项病例对照研究，总计6365例病例和9998例对照。在总体分析中，未发现PROGINS等位基因与卵巢癌风险之间存在统计学显著关联，但分层分析显示，对于白种人、从未使用过口服避孕药（OC）的人群以及浆液性肿瘤患者，携带突变的PROGINS等位基因与卵巢癌风险存在统计学显著的OR值。然而，在基于种族和组织学类型的总体分析及亚组分析中，均未观察到+331G/A多态性与卵巢癌易感性之间存在显著关联。这项荟萃分析提供了证据，表明PROGINS等位基因在卵巢癌患者中，尤其是在未使用OC的患者和浆液性癌患者中出现的频率更高，这表明PROGINS可能是一种风险修饰因子。即使在按种族和组织学类型进行的分层分析中，也未发现+331G/A多态性与卵巢癌之间存在显著关联。仍需要更详细且设计良好的研究来证实PROGINS等位基因在卵巢癌发展中的作用。
